Amylyx pharmaceuticals inc AMLX.US 總覽分析

美股醫療保健
(AMLX 無簡報檔)

AMLX 投資分析

看多重點:

  • 價值≥4
  • 股利≥2

分析結論

價值面評分低,若以價值投資為目標且有長期投資部位,需要嚴格執行自己的出場計畫來減持部位

AMLX 近期報酬表現

-0.22%

Amylyx pharmaceuticals inc

4.57%

同產業平均

3.26%

S&P500

與 AMLX 同產業的標的表現

  • BCAX Bicara therapeutics inc
    價值 -趨勢 3 分波段 2 分籌碼 3 分股利 1 分
    查看更多

AMLX 公司資訊

Amylyx Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on three investigational therapies across several neurodegenerative and endocrine diseases. Its lead investigational asset is avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist. Avexitide has been evaluated as a treatment for Post-Bariatric Hypoglycemia (PBH) and congenital HI, two indications characterized by hyperinsulinemic hypoglycemia. In addition to avexitide, it is advancing AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol in Wolfram syndrome and progressive supranuclear palsy (PSP), and AMX0114 in amyotrophic lateral sclerosis (ALS). AMX0035 is designed to mitigate neurodegeneration by targeting endoplasmic reticulum stress and mitochondrial dysfunction, two cellular processes central to neuronal cell death and neurodegeneration. AMX0114 is an investigational antisense oligonucleotide.

AMLX 股價